Delta 4 GmbH (Delta4)

https://www.delta4.ai

LinkedIn: https://www.linkedin.com/in/delta4-ai-13a41a193/

Delta 4 is a drug discovery and development company, combining in-silico drug discovery and big data analysis with extensive expertise in molecular biology and clinical development to a powerful proprietary drug discovery platform. This platform generates promising drug candidates annotated with biological and medical information, resulting in a fast track to establish a clinical proof of concept. The Company focuses on the discovery of novel indications for approved drugs (drug repositioning). In its first therapeutic area, focal segmental glomerulosclerosis (FSGS), a devastating renal disease with high and urgent medical need, Delta 4 has identified and pre-clinically validated promising drug candidates that are currently prepared for clinical proof-of-concept. In 2020, the Company applied its drug discovery platform to additional indications. As a result, Delta 4 has readied a potential COVID-19 therapy for Phase 1 development and filed four patent applications for compounds in two indications. *

	Start	2019-01-01 established
	Industry	AI-based drug discovery software
	Industry 2	drug repositioning services
	Person	Herpel, Kurt (Delta 4 202006 CEO)
	Person 2	Steininger, Alfred (Delta 4 202107– CFO)

	Region	Wien (Vienna)
	Country	Austria
	Street	23 Alser Str. Top 30
	City	1080 Wien
	Tel	+43-681-817051-48
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Delta 4 GmbH. (4/7/21). "Press Release: Delta 4 Announces Closing of Multi-million Series A Financing Round". Vienna.

		Record changed: 2023-06-26